How Ro Went From Roman to a Consumer Health Platform
Ro is one of the most useful telehealth companies to study because its story is not a straight line.
It began with a narrow, awkward, high-intent problem: erectile dysfunction.
It then expanded aggressively, raised enormous amounts of capital, bought infrastructure, acquired adjacent health companies, built pharmacy and diagnostic capabilities, and tried to evolve from a men’s-health brand into a broad direct-to-patient healthcare platform.
That expansion created both growth and friction.
At one point, Ro was valued at roughly $7 billion. It had raised more than $1 billion, operated a nationwide pharmacy network, acquired Modern Fertility, acquired Workpath, acquired Kit, expanded into mental health, skincare, fertility, diagnostics, and in-home care, and was trying to become a kind of operating system for consumer healthcare.
But broad expansion did not automatically mean easy growth.
TechCrunch reported in 2021 and 2022 that Ro was struggling to meaningfully diversify beyond its original Roman business, dealing with internal tension, executive turnover, and eventually layoffs as the company narrowed its focus.
Then the market changed.
GLP-1s exploded.
Ro had the infrastructure, brand, provider network, pharmacy capabilities, patient base, software, insurance workflows, and acquisition expertise to move aggressively into weight management.
By 2026, Ro had become one of the most visible direct-to-patient GLP-1 platforms in the country, working directly with Novo Nordisk and Eli Lilly, offering multiple FDA-approved GLP-1 options, serving more than three million members, and launching a national “Healthier on Ro” campaign with Serena Williams that included the company’s first Super Bowl ad.
That arc is what makes Ro worth studying.
Ro is not just a telehealth success story. It is a lesson in wedge markets, vertical integration, over-expansion, category timing, and what happens when a company survives long enough for its infrastructure to meet the right market.
The Genius of Starting With a Problem People Were Already Searching For
When Roman launched in 2017, it did not try to become the future of healthcare on day one.
It started with erectile dysfunction.
That was strategically brilliant for several reasons.
First, the problem was common.
Second, the problem was emotionally important.
Third, many men were embarrassed to discuss it in person.
Fourth, the patient journey could often be handled through a telehealth workflow when clinically appropriate.
Fifth, there was existing search demand.
And sixth, there was a clear product at the end of the journey.
TechCrunch’s original 2017 coverage described Roman as an online medical review and pharmacy experience for erectile dysfunction medications including Viagra, Cialis, and generics.
That is a much easier customer-acquisition proposition than launching with:
“A new integrated healthcare platform for all your wellness needs.”
People knew what problem they had.
They knew what outcome they wanted.
Roman simply reduced the embarrassment, friction, and inconvenience between problem and solution.
Lesson 1: A Narrow Wedge Can Build a Huge Company
Founders often believe starting narrow limits the size of the opportunity.
Ro demonstrates the opposite.
A narrow wedge can create:
- a clear customer
- a clear acquisition message
- a clear offer
- a clear conversion path
- a clear product-market-fit test
- a base of customers you can later cross-sell
Roman did not need to convince men they cared about “integrated health.”
It needed to answer a much simpler question:
Do you want a convenient, discreet way to address this specific problem?
That is the kind of offer performance marketers can scale.
Ro Then Tried to Become Much Bigger Than Roman
Once Roman proved demand, Ro began expanding aggressively.
The company launched additional verticals, developed Ro Pharmacy, expanded into mental health and skincare, acquired Modern Fertility, acquired Workpath for in-home services, and acquired Kit for at-home diagnostics.
By 2022, Ro said it had built ten pharmacy fulfillment centers, added more than 1,000 generic medications to its formulary, and reached patients in nearly every county in the United States.
Ro’s stated goal was no longer simply telehealth.
It wanted to become a direct-to-patient healthcare platform that connected virtual care, pharmacy, diagnostics, labs, and in-home services.
That is a very different company.
The Strategic Bet: Vertical Integration
Many telehealth companies take the MEDVi-style path and rent large portions of infrastructure.
Ro made a different bet.
It increasingly tried to own or tightly control more of the stack.
Ro built and operated pharmacy infrastructure. It acquired Workpath to add in-home care. It acquired Kit to bring diagnostics and laboratory capability closer to the platform. It acquired Modern Fertility to deepen women’s health.
Today Ro describes itself as the only U.S. company integrating nationwide telehealth, pharmacy, at-home testing, labs, and diagnostics.
Its internal technology messaging is explicit about the philosophy: build a healthcare operating system from the ground up and own the end-to-end patient journey.
That has major advantages.
Lesson 2: Owning More of the Stack Can Improve Control
Vertical integration can create advantages in:
- patient experience
- data quality
- speed of iteration
- pharmacy economics
- fulfillment
- clinical workflows
- diagnostics
- cross-sell
- retention
- research
If the systems are integrated well, the customer does not feel like they are moving between six different companies.
That can create a much smoother experience.
It can also create better data.
Ro now says its ro.OS platform connects telehealth, labs, pharmacy, and insurance concierge services, giving the company a large real-world dataset across patient behavior, outcomes, adherence, labs, access, and treatment patterns.
That data can become a strategic asset.
But Vertical Integration Is Expensive
Here is the part founders often forget.
Owning the stack creates control.
It also creates cost.
Every piece of infrastructure creates people, systems, compliance obligations, management overhead, and capital requirements.
Ro raised $500 million in a 2021 Series D. TechCrunch reported that the company had raised more than $876 million by that point. Ro then raised another $150 million from existing investors in 2022 at a reported $7 billion valuation.
That money gave Ro the ability to build and buy infrastructure most startups could never afford.
It also created pressure.
Once a company is valued at $5 billion or $7 billion, good growth is not enough.
It needs very large growth.
Lesson 3: Capital Changes the Definition of Success
A bootstrapped telehealth company doing $10 million in revenue can be a fantastic business.
A venture-backed telehealth company valued at $7 billion cannot survive on the same economics.
Capital raises the ceiling.
It also raises the required floor.
That means every founder needs to understand what kind of company they are actually building.
Do you want:
- a profitable $5 million business?
- a $50 million direct-to-consumer brand?
- a national healthcare platform?
- a venture-scale infrastructure company?
Those are not the same game.
Ro’s Expansion Became a Warning About Going Too Broad Too Fast
Ro’s growth was not frictionless.
In 2021, TechCrunch reported concerns from current and former employees that Ro was struggling to generate enough growth outside Roman despite the company’s expansion into multiple categories.
In 2022, Ro cut 18% of its workforce and said it needed to manage expenses, improve efficiency, and align resources to strategy.
Executives also departed during that period.
The point is not to turn this into gossip.
The strategic lesson is much more useful.
Expanding the product catalog is not the same thing as expanding product-market fit.
A company can launch ten new categories without finding a second category as strong as the first.
Lesson 4: Do Not Confuse More Products With More Growth
This is one of the easiest traps in telehealth.
Once you have providers and infrastructure, adding another condition feels easy.
Men’s health.
Hair loss.
Skincare.
Mental health.
Fertility.
Weight management.
Sleep.
Hormones.
But every category has different:
- customer awareness
- competition
- CAC
- LTV
- clinical complexity
- retention
- pharmacy economics
- search demand
- emotional intensity
The fact that you can offer something does not mean you should.
A second vertical should earn its place by economics, not by organizational enthusiasm.
Then GLP-1s Changed Ro’s Growth Story
This is where timing meets infrastructure.
When GLP-1 demand exploded, Ro was in a very different position from a startup entering the category from scratch.
It already had:
- millions of members
- a national telehealth footprint
- consumer healthcare brand awareness
- provider systems
- pharmacy infrastructure
- labs and diagnostic capabilities
- insurance workflows
- performance-marketing expertise
- a large existing patient database
The market had finally produced a healthcare category big enough to match the infrastructure Ro had been building.
Ro launched its Body Program around obesity treatment and built a membership model that includes provider support, coaching, insurance assistance, weight tracking, dose logging, and labs when clinically appropriate.
By 2026, Ro was directly integrated with Novo Nordisk and Eli Lilly distribution pathways for major branded GLP-1 products.
Ro had moved from selling telehealth access to participating in the direct-to-patient distribution infrastructure of two of the world’s most important pharmaceutical companies.
Lesson 5: Infrastructure Becomes More Valuable When the Right Category Arrives
Infrastructure can look excessive before the market catches up.
Then suddenly it becomes a moat.
A company that already has:
- patients
- clinical operations
- software
- pharmacy
- labs
- customer support
- brand
- acquisition systems
can move much faster when a large new category appears.
This is the second act of the Ro story.
The infrastructure that once looked expensive became strategically valuable when GLP-1s turned obesity medicine into one of the largest direct-to-consumer healthcare opportunities in years.
Ro’s Manufacturer Relationships Matter
In December 2024, Ro announced an integration with Eli Lilly’s LillyDirect self-pay pharmacy channel for Zepbound.
In April 2025, Ro integrated with NovoCare Pharmacy for Wegovy.
By 2026, Ro was participating in nationwide launches for newer GLP-1 formats including the Wegovy pill and Zepbound KwikPen.
Those relationships matter because they move Ro closer to the manufacturer.
That creates advantages around:
- availability
- authentic branded medication
- cash-pay pricing
- patient experience
- distribution reliability
- launch timing
That is very different from simply writing a prescription and hoping the patient can fill it somewhere.
Lesson 6: Distribution Relationships Can Become a Moat
Telehealth founders often obsess over acquisition.
Acquisition matters.
But supply and fulfillment can become equally important.
If two companies can generate identical demand but one can get patients authentic medication faster, more reliably, and at a better price, that becomes a conversion and retention advantage.
In healthcare, operations can be marketing.
Ro Has Also Learned to Sell the Category, Not Just the Medication
Ro’s current weight-loss marketing does not simply advertise a drug.
It sells a care experience.
The membership includes access to licensed providers, ongoing messaging, side-effect management, dose adjustments, coaching, weight tracking, and insurance support.
That matters because branded medications increasingly have price parity across multiple direct channels.
If everyone can access similar cash-pay manufacturer pricing, differentiation shifts toward the care layer.
The question becomes:
Why should the patient choose Ro rather than another telehealth platform or a manufacturer-direct option?
That is a much harder marketing problem.
Lesson 7: When Product Pricing Converges, Experience Becomes the Offer
If five telehealth companies offer the same medication at the same manufacturer-supported cash price, the drug is no longer the differentiator.
The differentiator becomes:
- speed
- trust
- provider support
- insurance assistance
- follow-up
- interface
- brand
- education
- convenience
This will increasingly matter as pharmaceutical companies expand direct-to-patient channels.
The Serena Williams Strategy Is Bigger Than Celebrity Marketing
Ro’s 2025 partnership with Serena Williams and its 2026 Super Bowl campaign are interesting because they signal a major shift in the company’s growth strategy.
Roman originally grew through performance marketing around highly specific problems.
Ro is now investing in national brand building.
The “Healthier on Ro” campaign spans television, digital, paid social, out-of-home advertising, and a Super Bowl commercial.
That is not cheap direct response.
It is category-scale brand advertising.
The goal is no longer simply getting one more ED prescription or one more GLP-1 patient.
The goal is making Ro synonymous with direct-to-patient healthcare.
Lesson 8: Performance Marketing Builds Demand Capture. Brand Can Expand the Market.
Search and direct response are excellent when customers already know what they want.
Brand marketing becomes more valuable when a company wants to shape how a large audience thinks about a category.
Ro’s celebrity strategy appears designed to normalize treatment, reduce stigma, and position Ro as a trusted place to start.
Serena Williams is especially powerful for GLP-1 marketing because she neutralizes one of the biggest emotional objections to obesity treatment:
“You just need more discipline.”
It is difficult to make a lack-of-discipline argument about one of the greatest athletes in history.
That is strategically smart positioning.
Ro Has Turned Its Patient Data Into an Authority Asset
Another important part of Ro’s evolution is research.
The company now publishes real-world evidence around GLP-1 use, adherence, outcomes, barriers to care, and patient experience.
Ro says its data has supported peer-reviewed research and more than 30 scientific abstracts.
This is a major authority move.
Healthcare brands that only publish marketing content remain marketing brands.
Healthcare brands that publish credible, useful data can begin participating in the scientific and policy conversation.
Lesson 9: Original Data Is One of the Strongest Forms of Authority
This is something almost every telehealth company should think about.
If you have thousands of patients, you likely have insights nobody else has.
You may be able to publish anonymized, aggregated research on:
- time to treatment
- drop-off points
- insurance approval rates
- adherence
- retention
- patient satisfaction
- clinical outcomes
- barriers to care
- regional differences
Done correctly and ethically, that data can create links, media coverage, academic interest, and authority that generic blog content cannot.
The Ro App Is Part of the Retention Strategy
Ro has also pushed care into a unified app experience.
That is strategically important because telehealth businesses can become transactional.
A patient comes in.
Gets a prescription.
Leaves.
The app changes the relationship.
It creates a place for messaging, treatment management, tracking, refills, education, and additional services.
That increases the chance the customer relationship survives beyond the first prescription.
Lesson 10: The Real Business Is the Relationship, Not the First Order
One of Ro’s most revealing historical metrics came from its 2022 funding announcement.
The company said one in five patients was already using Ro for more than one treatment.
That is the architecture of a platform.
The first purchase is customer acquisition.
The second and third purchases are where the relationship becomes strategically valuable.
Ro vs MEDVi: Two Different Telehealth Growth Models
MEDVi and Ro are useful to compare because they demonstrate almost opposite approaches.
MEDVi
Lean internal team. Heavy outsourcing. AI-assisted execution. Aggressive performance and affiliate marketing. Minimal owned infrastructure.
Ro
Large capital base. Owned pharmacy infrastructure. Acquisitions. Diagnostics. Labs. In-home care. Heavy vertical integration. National brand building.
Neither model is automatically right.
The strategic question is what the company is trying to become.
A founder validating a niche telehealth offer probably should not imitate Ro’s capital intensity.
A company attempting to become a national healthcare platform probably cannot remain a simple marketing layer forever.
What I Would Copy From Ro
1. Start With a Painfully Specific Wedge
Roman was not broad. That was a strength.
2. Remove Emotional Friction
Telehealth works especially well where embarrassment or inconvenience delays care.
3. Build Lifetime Value
The value of a patient relationship rises when multiple clinically appropriate needs can be served over time.
4. Own Strategic Infrastructure When Scale Justifies It
Do not build everything on day one. But own the pieces that become genuine competitive advantages.
5. Build Direct Manufacturer Relationships
Supply, pricing, and distribution matter.
6. Turn Data Into Research
Original evidence creates authority.
7. Use Brand to Expand Beyond Direct Response
Performance marketing captures demand. Brand can make the market larger.
8. Build an App or Member Experience That Creates Continuity
Retention is easier when the customer relationship lives somewhere.
What I Would Not Copy
I would not raise enormous amounts of capital without understanding the growth expectations that come with it.
I would not expand into ten categories simply because the infrastructure makes it technically possible.
I would not assume acquisitions automatically integrate well.
I would not confuse a large product catalog with product-market fit.
I would not vertically integrate before the economics justify the complexity.
I would not build infrastructure that the market may never need.
The Biggest Ro Lesson: Your Second Act Can Be Bigger Than Your First
This may be the most important insight.
Roman gave Ro its wedge.
It created customer-acquisition expertise, healthcare operations, brand credibility, and capital.
But the category that may ultimately define Ro is not erectile dysfunction.
It may be obesity medicine and broader goal-oriented healthcare.
That is strategically encouraging for founders.
Your first product does not have to be your final identity.
But the first product needs to create something transferable:
- customers
- cash flow
- brand
- data
- infrastructure
- distribution
- expertise
If it does, the second act can be much larger.
The Bottom Line
Ro’s story is more complicated than a typical startup success story, which is exactly why it is so useful.
It started narrow and grew fast.
It raised massive capital.
It vertically integrated.
It expanded aggressively.
It experienced the pain of trying to grow beyond its original wedge.
Then GLP-1s created a category that matched the infrastructure Ro had spent years building.
Today Ro says it has supported more than three million patients and delivered more than 20 million treatments. It operates across telehealth, pharmacy, labs, diagnostics, fertility, sexual health, hair, skin, and weight management. It has direct relationships with major pharmaceutical manufacturers and is investing in national brand campaigns that would have been almost unimaginable for a telehealth startup a few years ago.
The lesson is not that every telehealth founder should build Ro.
Most should not.
The lesson is to understand the sequence.
Start with a specific problem.
Earn product-market fit.
Build customer relationships.
Add infrastructure only when it increases advantage.
Expand when a second market earns the right to receive resources.
And stay alive long enough for the right category to meet the machine you built.
That is how Roman became Ro.
Sources and Further Reading
- TechCrunch: Roman is a cloud pharmacy for erectile dysfunction
- TechCrunch: Ro raises $500M to grow its remote and in-home primary care platform
- Ro: $150M funding and platform expansion
- TechCrunch: Ro cuts 18% of staff
- Ro acquires Modern Fertility
- Ro acquires Workpath
- Ro acquires Kit
- Ro and LillyDirect Zepbound integration
- Ro and NovoCare Wegovy integration
- Ro launches Healthier on Ro with Serena Williams
- Ro Real-World Evidence and Research Hub
For another telehealth growth model, read How MEDVi Grew to $401 Million.
For the underlying software and operational architecture, see Best Telehealth Software Platforms: 2026 Buyer’s Guide.
